Evidence map›Paper›PMID 31050706›Full record

ReviewEndocrine reviews2019

Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Antonino Di Pino, Ralph A DeFronzo

Open access · bronzeAbstract readReview
In one paragraph

Review in Endocrine reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 303 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
303citing papers in PubMed, 5 pooled it
29.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

303 citing papers in PubMed, 5 syntheses or guidelines pooled it, 519 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

243 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Antonino Di PinoDiabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas.
Ralph A DeFronzoDiabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas.
The University of Texas Health Science Center at San Antonio · US

Funding

SGLT2 Inhibitors, Ketogenesis, and KetoacidosisR01DK024092 · NIDDK · YALE UNIVERSITY · PI RALPH A DEFRONZO · 1986 to 2026
$12.7M
Regulation of Hepatic and Peripheral Glucose MetabolismR56DK024092 · NIDDK · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI DEFRONZO, RALPH A · 2005 to 2005
$73k
NIDDK NIH HHS R01 DK024092NIDDK NIH HHS R56 DK024092
6 · The paper itself

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.

Indexed as

Insulin ResistanceAnimalsAtherosclerosisDiabetes Mellitus, Type 2HumansHypoglycemic AgentsThiazolidinedionesHypoglycemic AgentsThiazolidinediones

Identifiers

PMID31050706
PMCPMC7445419
OpenAlexW2945554427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.